SAREPTA THERAPEUTICS, INC. Amortization of Debt Issuance Costs
SAREPTA THERAPEUTICS, INC. (SRPT) reported Amortization of Debt Issuance Costs of $12.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $8.60M, a 561.54% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $1.10M, a 8.33% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-12-31 was $1.30M, a 0.00% change year-over-year.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2024-09-30 was $1.20M, a 0.00% change year-over-year.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2025 was $12.10M, a 142.00% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2024 was $5.00M, a 3.85% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2023 was $5.20M, a 30.67% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2022 was $7.50M, a 1.32% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.70M derived: sum of 2 quarters · filed 2026-03-02 | $12.10M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-06 | $3.50M 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.50M derived: sum of 2 quarters · filed 2026-03-02 | $3.80M derived: sum of 3 quarters · filed 2026-03-02 | $5.00M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.50M derived: sum of 2 quarters · filed 2025-11-06 | $3.70M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-07 | $2.50M 10-Q · filed 2024-08-07 | ||
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.50M derived: sum of 2 quarters · filed 2026-03-02 | $3.70M derived: sum of 3 quarters · filed 2026-03-02 | $5.20M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.20M 10-Q · filed 2024-11-06 | $2.40M derived: sum of 2 quarters · filed 2024-11-06 | $3.90M 10-Q · filed 2024-11-06 | $5.40M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.20M 10-Q · filed 2024-08-07 | $2.70M 10-Q · filed 2024-08-07 | $4.20M derived: sum of 3 quarters · filed 2025-02-28 | $6.20M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.50M 10-Q · filed 2023-05-02 | $3.00M derived: sum of 2 quarters · filed 2025-02-28 | $5.00M derived: sum of 3 quarters · filed 2025-02-28 | $7.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.50M derived: sum of 2 quarters · filed 2025-02-28 | $5.50M derived: sum of 3 quarters · filed 2025-02-28 | $7.50M 10-K · filed 2025-02-28 |
| 2022-09-30 | $2.00M 10-Q · filed 2023-11-01 | $4.00M derived: sum of 2 quarters · filed 2023-11-01 | $6.00M 10-Q · filed 2023-11-01 | $8.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.00M 10-Q · filed 2023-08-02 | $4.00M 10-Q · filed 2023-08-02 | $6.00M derived: sum of 3 quarters · filed 2024-02-28 | $7.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-02 | $4.00M derived: sum of 2 quarters · filed 2024-02-28 | $5.90M derived: sum of 3 quarters · filed 2024-02-28 | |
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.90M derived: sum of 2 quarters · filed 2024-02-28 | $7.60M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-02 | $5.60M 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | $25.50M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |